Journal rankings · indicator year 2023
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Domain ranking · 2023
Health Sciences journal rankings 2023
5,618 ranked journals · Domain
Health Sciences has 5,618 ranked journals in 2023. The median journal has an OJR of 0.68, below the world average of 1.00, unchanged on 2022; Q1 starts at OJR 1.10. The top three are CA A Cancer Journal for Clinicians, MMWR Surveillance Summaries, and The Lancet.
Ranks and citation indicators: 2023. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2020–2022, the window the 2023 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Fields in Health Sciences (5)
Up to All journals5,618 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2022. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2020–2022, the window the 2023 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2020–2022 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2014 to 2023. | Compare |
|---|---|---|---|---|---|---|---|
1CA A Cancer Journal for CliniciansOAWiley · United States | 147.65Q1 | 694.53 143.18 up from 2022 | 89 | 100% | $4,330 | ||
2MMWR Surveillance SummariesOACenters for Disease Control and Prevention · United States | 23.23Q1 | 55.38 21.67 down from 2022 | 30 | 100% | — | ||
3The LancetElsevier BV · Netherlands | 13.34Q1 | 32.77 18.89 down from 2022 | 2,713 | 55% | $7,890 | ||
4New England Journal of MedicineMassachusetts Medical Society · United States | 13.12Q1 | 33.51 19.42 down from 2022 | 3,234 | 31% | — | ||
5Nature MedicineNature Portfolio · United States | 12.39Q1 | 41.03 17.71 down from 2022 | 1,073 | 54% | $12,690 | ||
6Nature Reviews Disease PrimersNature Portfolio · United Kingdom | 12.10Q1 | 70.36 1.36 up from 2022 | 156 | 30% | — | ||
7Endocrine ReviewsOxford University Press · United States | 10.25Q1 | 25.49 1.90 up from 2022 | 103 | 92% | $3,750 | ||
8Periodontology 2000Wiley · United Kingdom | 10.21Q1 | 20.07 3.13 down from 2022 | 140 | 85% | $4,430 | ||
9Clinical Microbiology ReviewsAmerican Society for Microbiology · United States | 9.00Q1 | 21.91 8.98 down from 2022 | 100 | 100% | — | ||
10The Lancet OncologyElsevier BV · United Kingdom | 7.50Q1 | 21.08 4.65 down from 2022 | 1,008 | 35% | $7,280 | ||
11CirculationLippincott Williams & Wilkins · United States | 7.43Q1 | 20.32 1.24 down from 2022 | 1,626 | 7% | — | ||
12Journal of Hematology & OncologyOABioMed Central · United Kingdom | 7.25Q1 | 24.38 0.44 down from 2022 | 527 | 100% | $4,990 | ||
13Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 7.22Q1 | 20.28 1.84 down from 2022 | 1,437 | 45% | — | ||
14MMWR Morbidity and Mortality Weekly ReportOACenters for Disease Control and Prevention · United States | 7.04Q1 | 24.12 11.40 down from 2022 | 938 | 100% | — | ||
15The Lancet Diabetes & EndocrinologyElsevier BV · Netherlands | 6.91Q1 | 19.91 0.30 down from 2022 | 457 | 48% | $7,280 | ||
16Progress in Retinal and Eye ResearchElsevier BV · Netherlands | 6.83Q1 | 15.15 2.11 down from 2022 | 161 | 59% | $6,710 | ||
17The Lancet NeurologyElsevier BV · Netherlands | 6.76Q1 | 19.28 0.27 down from 2022 | 575 | 46% | $7,280 | ||
18Cancer CellCell Press · Netherlands | 6.59Q1 | 21.68 3.98 down from 2022 | 571 | 100% | $10,400 | ||
19Kidney International SupplementsElsevier BV · United States | 6.54Q1 | 22.96 15.38 up from 2022 | 40 | — | $3,500 | ||
20Cancer DiscoveryAmerican Association for Cancer Research · United States | 6.50Q1 | 24.60 3.66 up from 2022 | 577 | 31% | — | ||
21Nature Reviews Clinical OncologyNature Portfolio · United Kingdom | 6.27Q1 | 32.92 2.70 up from 2022 | 369 | 14% | — | ||
22European Heart JournalOxford University Press · United Kingdom | 6.10Q1 | 16.51 1.23 down from 2022 | 1,752 | 93% | $5,922 | ||
23The Lancet Respiratory MedicineElsevier BV · Netherlands | 6.10Q1 | 17.78 15.40 down from 2022 | 691 | 59% | $7,280 | ||
24npj Digital MedicineOANature Portfolio · United States | 5.87Q1 | 16.58 3.15 down from 2022 | 505 | 100% | $4,090 | ||
25The Lancet Digital HealthOAElsevier BV · United Kingdom | 5.75Q1 | 19.42 0.33 down from 2022 | 345 | 100% | $6,680 | ||
26Journal of the American College of CardiologyElsevier BV · United States | 5.67Q1 | 13.21 1.86 down from 2022 | 1,824 | 96% | $7,166 | ||
27Alcohol researchOANational Institute on Alcohol Abuse and Alcoholism · United States | 5.54Q1 | 8.40 1.97 down from 2022 | 45 | 100% | — | ||
28Journal of HepatologyElsevier BV · Denmark | 5.48Q1 | 16.13 0.77 down from 2022 | 1,182 | 16% | $5,500 | ||
29NEJM EvidenceUnited States | 5.02Q1 | 11.51 1.68 up from 2022 | 155 | 31% | — | ||
30GutBMJ · United Kingdom | 4.94Q1 | 15.21 1.46 down from 2022 | 991 | 54% | — | ||
31The Lancet. Gastroenterology & hepatologyElsevier BV · United Kingdom | 4.86Q1 | 14.58 1.45 down from 2022 | 535 | 31% | $7,280 | ||
32Annals of OncologyElsevier BV · Netherlands | 4.83Q1 | 17.06 0.06 down from 2022 | 995 | 100% | $5,080 | ||
33Molecular NeurodegenerationOABioMed Central · United Kingdom | 4.78Q1 | 14.90 0.95 down from 2022 | 218 | 100% | $3,090 | ||
34Nature Reviews Gastroenterology & HepatologyNature Portfolio · United Kingdom | 4.62Q1 | 18.21 6.29 down from 2022 | 451 | 24% | — | ||
35Nature CancerNature Portfolio · United States | 4.60Q1 | 15.97 1.13 up from 2022 | 431 | 52% | $12,690 | ||
36JAMA NeurologyAmerican Medical Association · United States | 4.49Q1 | 10.80 4.61 down from 2022 | 716 | 63% | — | ||
37The Lancet Infectious DiseasesElsevier BV · Netherlands | 4.45Q1 | 16.17 10.73 down from 2022 | 1,190 | 58% | $7,280 | ||
38Journal of the National Comprehensive Cancer NetworkNational Comprehensive Cancer | 4.44Q1 | 13.54 0.74 up from 2022 | 570 | 56% | — | ||
39Diabetes CareAmerican Diabetes Association · United States | 4.40Q1 | 12.94 1.17 down from 2022 | 1,511 | 89% | — | ||
40The Lancet Child & Adolescent HealthElsevier BV · United Kingdom | 4.39Q1 | 11.45 5.33 down from 2022 | 442 | 38% | $6,680 | ||
41Current Obesity ReportsSpringer Science+Business Media · United States | 4.37Q1 | 12.13 0.74 up from 2022 | 119 | 64% | $5,790 | ||
42Journal of Educational Evaluation for Health ProfessionsOAKorea Health Insurance Licensing Examination Institute · South Korea | 4.35Q1 | 14.31 7.62 up from 2022 | 115 | 100% | — | ||
43AutophagyTaylor & Francis · United States | 4.34Q1 | 11.10 0.37 down from 2022 | 603 | 100% | — | ||
44Translational NeurodegenerationOABioMed Central · China | 4.27Q1 | 11.57 1.52 down from 2022 | 144 | 100% | $2,990 | ||
45DrugsAdis, Springer Healthcare · New Zealand | 4.25Q1 | 14.61 0.95 up from 2022 | 466 | 77% | $5,990 | ||
46Nature Reviews CardiologyNature Portfolio · United Kingdom | 4.21Q1 | 16.28 1.94 down from 2022 | 481 | 24% | — | ||
47European UrologyElsevier BV · Switzerland | 4.21Q1 | 10.42 1.77 down from 2022 | 740 | 8% | $5,250 | ||
48Medical Image AnalysisElsevier BV · United Kingdom | 4.12Q1 | 12.36 0.41 up from 2022 | 836 | 54% | $4,170 | ||
49Alzheimer s & DementiaWiley · United States | 4.12Q1 | 11.83 1.35 down from 2022 | 743 | 91% | $4,200 | ||
50Food SecuritySpringer Science+Business Media · Netherlands | 4.06Q1 | 7.80 1.78 down from 2022 | 305 | 67% | $2,790 |
Fields of Health Sciences, compared.
Journals
Citations made in 2023. Corpus-wide, 88.9% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
1,216 additional Health Sciences journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2020–2022, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2023. Publication window: 2020–2022. How these summaries are calculated
- Ranked journals
- 5,618
- Window papers (baseline)
- 3,490,788 +22.6% from indicator year 2020
- Median OJR
- 0.6776 -7.8% from indicator year 2020
- Rising journals (2025)
- 464
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2020–2022 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 2,007 | 2,150 | 2,285 | 2,374 | 2,486 | 2,626 | 2,757 | 2,922 | 3,062 | 3,193 | 3,364 | 3,591 | 3,809 | 4,129 | 4,361 | 4,544 | 4,757 | 4,979 | 5,239 | 5,390 | 5,462 | 5,563 | 5,606 | 5,618 | 5,549 | 5,406 | |
| Window papers (baseline) | 813,419 | 909,304 | 974,228 | 1,051,248 | 1,094,845 | 1,200,886 | 1,317,521 | 1,455,690 | 1,577,275 | 1,733,757 | 1,887,930 | 2,035,231 | 2,126,669 | 2,204,628 | 2,320,572 | 2,437,477 | 2,534,543 | 2,585,157 | 2,649,222 | 2,728,712 | 2,846,138 | 3,078,764 | 3,332,730 | 3,490,788 | 3,507,496 | 3,550,948 | |
| Median OJR | 0.50 | 0.53 | 0.56 | 0.59 | 0.61 | 0.63 | 0.6778 | 0.70 | 0.726 | 0.748 | 0.767 | 0.773 | 0.78 | 0.741 | 0.76 | 0.750 | 0.737 | 0.727 | 0.71 | 0.725 | 0.735 | 0.680 | 0.67 | 0.6776 | 0.681 | 0.69 |
| Measure | Category statistic | Eligible population |
|---|---|---|
| Journal self-citation share | Median: 3.3% | 4,151 journals |
| Retracted papers per 1,000 | Pooled rate: 1.372 per 1,000 | 4,101 journals |
| Output growth | Median: -6.3% | 5,009 journals |
| Open access share | Median: 100.0% | 5,406 journals |
| Listed APC (USD) | Median including $0 listed prices: $3,090 | 2,959 ranked journals with a known listed price, including $0 listed prices |
| International collaboration share | Median: 20.2% | 5,241 journals |
| Review share | Median: 2.7% | 5,406 journals |
| Articles-only OJR | Median: 0.70 | 5,372 journals |
| Uncited share | Median: 37.7% | 5,406 journals |
| Citation concentration | Median: 46.2% | 5,398 journals |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.